Recent regulatory scrutiny in Germany has cast a spotlight on misoprostol (Angusta) and its role in labour induction, raising significant safety concerns. As this conversation unfolds across Europe, healthcare professionals are re-evaluating their induction protocols and looking to non-pharmacological methods like DILAPAN-S as a safer alternative.
